Anti-IgE Antibody Dosing for Multiple Food Allergy Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for food allergies, such as oral immunotherapy, are inadequate for patients allergic to multiple foods, and there is a need for improved therapies to prevent or reduce allergic reactions to food allergens, particularly in pediatric patients.
Innovation Solution
Administration of an anti-IgE antibody, such as omalizumab, at a specific dose and frequency to block IgE binding to the high-affinity IgE Receptor (FcεRI), reducing serum IgE levels and preventing allergic reactions to food allergens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If oral immunotherapy is used for peanut allergy, then treatment for peanut allergy is available, but treatment for multiple food allergies is inadequate
Solution Approach 1:
The anti-IgE antibody therapy provides universal protection against multiple food allergies simultaneously, rather than requiring separate treatments for each allergen. The therapy works across different food types (peanut, milk, egg, wheat, soy, fish, shellfish, tree nuts) by targeting the common IgE pathway, making it a multi-functional treatment approach that addresses the limitation of allergen-specific therapies.
2Ease of operation
If standard care (avoidance and emergency treatment) is used, then safety is maintained, but quality of life and dietary freedom are reduced
Solution Approach 1:
The anti-IgE antibody therapy provides preliminary protection by reducing serum IgE levels before allergic reactions can occur. This preventive approach allows patients to consume food allergens without experiencing dose-limiting symptoms, transforming the management strategy from reactive (avoidance and emergency treatment) to proactive (prevention through IgE reduction).
Solution Approach 2:
The therapy converts the harmful effect of IgE-mediated allergic reactions into a beneficial state by selectively reducing IgE levels. This allows patients to safely consume foods that would otherwise trigger severe reactions, turning the previously harmful allergen exposure into a safe and even beneficial dietary freedom.
3Reliability
If anti-IgE antibody is administered at high dose, then allergic reactions are prevented, but treatment cost and administration complexity increase
Solution Approach 1:
The therapy utilizes parameter changes in IgE levels to determine dosing requirements. By monitoring and adjusting the anti-IgE antibody dose based on individual IgE reductions and clinical response, the protocol optimizes the balance between protection effectiveness and administration complexity. This allows for personalized dosing that maintains reliability while reducing unnecessary complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces or prevents allergic reactions in pediatric patients with multiple food allergies, allowing them to consume food allergens without triggering dose-limiting symptoms, even in the absence of concurrent oral immunotherapy.
Implementation Method 1
Administration of an anti-IgE antibody, such as omalizumab, at a specific dose and frequency to block IgE binding to the high-affinity IgE Receptor (FcεRI)
Data Source
AI summary
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.